Prevalence and Incidence of Dopamine beta-hydroxylase deficiency

Dopamine beta-hydroxylase deficiency: Rare Disease

Dopamine beta-hydroxylase deficiency is listed as a "rare disease" by the Office of Rare Diseases (ORD) of the National Institutes of Health (NIH). This means that Dopamine beta-hydroxylase deficiency, or a subtype of Dopamine beta-hydroxylase deficiency, affects less than 200,000 people in the US population.

Ophanet, who are a consortium of European partners, currently defines a condition rare when if affects 1 person per 2,000. They list Dopamine beta-hydroxylase deficiency as a "rare disease". More information about Dopamine beta-hydroxylase deficiency is available from Orphanet

About prevalence and incidence statistics:

The term 'prevalence' of Dopamine beta-hydroxylase deficiency usually refers to the estimated population of people who are managing Dopamine beta-hydroxylase deficiency at any given time. The term 'incidence' of Dopamine beta-hydroxylase deficiency refers to the annual diagnosis rate, or the number of new cases of Dopamine beta-hydroxylase deficiency diagnosed each year. Hence, these two statistics types can differ: a short-lived disease like flu can have high annual incidence but low prevalence, but a life-long disease like diabetes has a low annual incidence but high prevalence. For more information see about prevalence and incidence statistics.

Search Specialists by State and City